| Studies |
Disease |
Age/sex |
Experiment
N=number |
Route |
Type of cells |
Oucome measures/ phase |
| Prasad et al. [30] |
Acute
Stroke |
30-70 yrs |
11(non randomized) |
Intravenous |
BM MNC |
No AE, seven patients had favourable outcomes. |
| Srivastava et al. [35] |
Chronic
stroke |
20-65yrs |
20(non randomized case control) |
Intravenous |
BM MNC & BM MSC |
No AE,
Modified barthel index statistically significant (p=0.04) |
| Prabhakar et al. [34] |
MND
(ALS) |
Mean 49.1 yrs |
10 (open label) |
Intrathecal |
BM MNC |
No AE, No significant deterioration in ALSFRS-R score |
| Srivastava et al. [35] |
Cerebral
Palsy/static
encephalopathy |
16-30yrs |
30 (open label) |
Intra-arterial |
BM MNC |
No AE, functional improvement observed. |
| Sharma et al. [36] |
DMD |
unknown |
150 (open label) |
Intrathecal and intramuscular |
BM MNC |
No AE, 53% cases increase in muscle strength |
| Sharma et al. [37] |
Cerebral
palsy
DMD |
unknown |
71 (open
label) |
Intrathecal /intramuscular |
BM MNC |
75% showed improvement in muscle tone, 50% in speech |
| Bhanot et al. [41] |
Chronic
spinal cord
injury |
18-52yrs |
13 (open
label) |
Intrathecal |
BM MSC |
No AE, improvement in ASIA scale |
| Ravi kumar et al. [40] |
Spinal
cord injury |
8-55yrs |
100 |
intrathecal |
BM MNC |
No AE, functional improvement observed |
| Venkataramana et al. [39] |
Parkinson’s disease |
22-62yrs |
7 (open
label) |
Stereotactic
Surgery |
BM MSC |
UPDRS score improved to 28%, 2.7 point change in Y & H scale |
| Pal et al. [42] |
Chronic
spinal cord injury |
unknown |
30 (open label) |
Intrathecal |
BM MSC |
No SAE |
| NCT01883661 |
Multiple Sclerosis |
18-65yrs |
15 (open label) |
Intravenous |
BM MSC+ UCMSC |
Phase 1/ 2 |
| NCT00976430 |
Parkinson’s disease |
35-70yrs |
5 (open label) |
Stereotactic |
BM MSC |
Phase 1 /2 |
| NCT01984814 |
ALS |
26-76yrs |
57 (open label) |
Intrathecal/ intramuscular |
BM MNC |
Phase 2 |
| NCT01834040 |
DMD |
4-20yrs |
30 (open label) |
Intravenous/ intralesional |
HUCMSC |
Phase 1 /2 |
| NCT01834066 |
DMD |
6-25yrs |
25 (open label) |
Intravenous |
BM MNC |
Phase 1 /2 |
| NCT02027246 |
Spinal
cord injury |
8mo-63yrs |
166 (open label) |
Intrathecal |
BM MNC |
Phase 1 |
| NCT02009124 |
Spinal
cord injury |
12mo-65yrs |
250/250 (non randomized) |
Intrathecal |
BM MNC |
Phase 2 |
| NCT01833975 |
Spinal
cord injury |
18-55yrs |
50 (open label) |
Unknown |
BM MNC |
Phase 1/ 2 |
| NCT01186679 |
Spinal
cord injury |
20-55yrs |
6/6 (non randomized) |
Intralesional /
Intrathecal |
BM MNC |
Phase 1 /2 |
| NCT01834053 |
Huntington’s chorea |
35-45yrs |
50 (open label) |
Intravenous |
BM MNC |
Phase 1 /2 |
